A class of HIV antiretroviral drugs known as CCR5 antagonists — which includes maraviroc (Selzentry) and vicriviroc — inhibit the invasion or spread of specific types of breast cancer cells that express CCR5 receptors, according to findings from a laboratory study published in the May 25, 2012, advance online edition of Cancer Research.
